1-6 of 6
Gail Klein
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Indolent Lymphoma: Well Tolerated, Fixed Duration Treatment Involving Bendamustine, Rituximab and Acalabrutinib for Front-Line Waldenström's Macroglobulinaemia That Induce Deep Clinical Responses

Adam Suleman, Kim Roos, Kathryn Mangoff, Yidi Jiang, Gail Klein, Rebecca McClure, Nicholas Allen Forward, Mona Shafey, Anna Nikonova, Michael Sebag, David MacDonald, Diego Villa, Irwindeep Sandhu, Mohammed Aljama, Jean-Francois Larouche, Heidi Simmons, Monica Gallucci, George A. Tomlinson, Neil Berinstein
Journal: Blood
Blood (2024) 144 (Supplement 1): 6291.
https://doi.org/10.1182/blood-2024-203317
Published: 2024
Journal Articles

Indolent Lymphoma: High CR and VGPR Rate with Fixed Duration Bendamustine, Rituximab and Acalabrutinib in Waldenstroms Macroglobulinaemia (BRAWM)

Neil Berinstein, Kim Roos, Kathryn Mangoff, Yidi Jiang, Gail Klein, Rebecca McClure, Nicholas Forward, Mona Shafey, Anna Nikonova, David MacDonald, Diego Villa, Irwindeep Sandhu, Mohammed Aljama, Jean-Francois Larouche, Monica Gallucci, Heidi Simmons
Journal: Blood
Blood (2023) 142 (Supplement 1): 3037.
https://doi.org/10.1182/blood-2023-186347
Published: 2023
Journal Articles

Intensity of Survivin Expression Correlates with Clinical and Biological Markers of Aggressive R/R DLBCL

Sila Usta, Alexandra Misura, Kim Roos, Iran Rashedi, Irina Amitai, Yidi Jiang, Kathryn Mangoff, Gail Klein, Nicholas Allen Forward, Douglas A. Stewart, Joy Mangel, George A. Tomlinson, Hubert Tsui, Neil Berinstein
Journal: Blood
Blood (2023) 142 (Supplement 1): 6124.
https://doi.org/10.1182/blood-2023-189200
Published: 2023
Journal Articles

Next Generation BTK Inhibitor Acalabrutinib with Bendamustine-Rituximab in First Line Waldenstrom's Macroglobulinemia: The Brawm Study

Neil L Berinstein, Gail Klein, Katerina Welsh, Rebecca McClure, Nicholas Allen Forward, Mona Shafey, Anna Nikonova, David MacDonald, Diego Villa, Irwindeep Sandhu, Mohammed A Aljama, Jean-François Larouche
Journal: Blood
Blood (2022) 140 (Supplement 1): 9383–9384.
https://doi.org/10.1182/blood-2022-169245
Published: 2022
Journal Articles

Clinical Effectiveness of Combination Immunotherapy DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

Neil L Berinstein, MD, Isabelle Bence-Bruckler, MD, Nicholas Allen Forward, MDMSc,FRCPC, Pierre Laneuville, MD FRCPC, Joy Mangel, MD FRCPC, Douglas A. Stewart, MD FRCPC, Irina Amitai, MD, Gail Klein, MSc, Nancy Pennell, BSc, Iran Rashedi, MD MSc, Kim Roos, BA, BSc, Yogesh Bramhecha, Rebekah Conlon, RN
Journal: Blood
Blood (2020) 136 (Supplement 1): 16.
https://doi.org/10.1182/blood-2020-136751
Published: 2020
Journal Articles

Combination of DPX-Survivac, Low Dose Cyclophosphamide, and Pembrolizumab in Recurrent/Refractory DLBCL: The Spirel Study

Neil L Berinstein, MD, Isabelle Bence-Bruckler, MD, Pierre Laneuville, MD FRCPC, Douglas A. Stewart, MD, Nicholas Allen Forward, MDMSc,FRCPC, Liam Smyth, MDFRCPath, Gail Klein, MSc, Nancy Pennell, BSc, Kim Roos, BA, BSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 3236.
https://doi.org/10.1182/blood-2019-125963
Published: 2019